1274-IMIREG:揭示免疫参与架构与预测免疫治疗反应的转录组特征 episode artwork

EPISODE · Jul 13, 2026 · 16 MIN

1274-IMIREG:揭示免疫参与架构与预测免疫治疗反应的转录组特征

from 聊聊Sci

这份研究介绍了一种名为 IMIREG 的新型转录组生物标志物,旨在提高癌症免疫检查治疗(ICB)的精准度。研究人员通过系统生物学方法,从转录因子的活性中提取出由 14 个调节子 构成的特征信号,能够更精准地评估肿瘤微环境中的免疫参与度。该指标在涵盖 16 种癌症类型的 50 个临床队列中得到了验证,其预测治疗效果的准确性显著优于现有的多种标志物。分析显示,IMIREG 高表达的肿瘤处于一种“已激活但受抑制”的特殊状态,这种状态对免疫药物高度敏感,且最容易在 T 细胞与巨噬细胞 协同作用时出现。研究进一步揭示,这种协同免疫状态在癌症转移阶段会大幅减弱,说明肿瘤在演进过程中存在免疫逃逸。最后,针对三阴性乳腺癌的动态追踪证实,IMIREG 可作为药效监测指标,在治疗早期即可预测患者的病理完全缓解情况。References:Lawal B, Sharma R, Gupta A, et al. IMIREG: a lineage-resolved regulon signature unveiling immune engagement archetypes and predicting immunotherapy response across diverse cancers[J]. NPJ Precision Oncology, 2026.前往小宇宙评论区与主播互动

Episode metadata supplied by the publisher feed · Published Jul 13, 2026

Embed this episode

Ready to play

1274-IMIREG:揭示免疫参与架构与预测免疫治疗反应的转录组特征

0:00 16:51

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of 聊聊Sci?

This episode is 16 minutes long.

When was this 聊聊Sci episode published?

This episode was published on July 13, 2026.

Can I download this 聊聊Sci episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!